Immuneering Corporation (IMRX)
NASDAQ
$3.74
-$0.10
(-2.64%)
Regular Market
Immuneering Corporation (IMRX) Live Price Chart
Last updated: 2026-11-12 15:28:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Immuneering Corporation (IMRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.74, with a market capitalization of $249.34M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.35 to $8.48. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$249.34M | |
$3.86 | |
$3.95 | |
$3.69 | |
$3.79 | |
103.40K | |
708.57K | |
-- | |
$8.48 | |
$3.35 | |
-- | |
-- |
Immuneering Corporation (IMRX) Stock Price Today
Immuneering Corporation (IMRX) is currently trading at $3.74 as of 2026-11-12 15:12:48, down 2.64% ($0.10) from the previous close of $3.79
During today's regular trading session, IMRX has traded between $3.69 and $3.95, with a trading volume of 103.40K shares. The current price is near the lower end of today's range.
Immuneering Corporation (IMRX) 7-Day Stock Price Change
Over the past seven days, Immuneering Corporation (IMRX) moved from $3.68 to $3.74, representing a gain of 1.52% ($0.06).
The stock traded between $3.35 and $3.95 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 732.70 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
IMRX 52-Week Price Position
Position in Range: 7.5%
52W Low$3.35
52W High$8.48
IMRX is currently trading at $3.74, placing it 7.5% of the way from its 52-week low of $3.35 to its 52-week high of $8.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Immuneering Corporation (IMRX)?
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Immuneering Corporation Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 65 |
| Exchange | NASDAQ |
| Company Website |
IMRX Stock Events
View the latest dividend and stock split events for Immuneering Corporation.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
IMRX News
Latest news related to Immuneering Corporation and IMRX stock.
- BenzingaRead Full Article
- BenzingaRead Full Article
Immuneering Enters Clinical Trial Collaboration With Astellas To Test Atebimetinib With CLDN18.2-Targeted Drugs In Pancreatic Cancer
- BenzingaRead Full Article
Immuneering Plans To Initiate Phase 2 Clinical Trial Evaluating Atebimetinib In Combination With Chemotherapy In Patients With Anaplastic Thyroid Cancer
- Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic thyroid cancer (ATC), a highly aggressive cancer with significant unmet need commonly
- BenzingaRead Full Article
Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients
- Collaboration aligns with Immuneering’s expanding strategy to provide a broad population of cancer patients with a wide set of treatment options -- Represents Immuneering’s fourth agreement with a pharma partner --
- BenzingaRead Full Article
Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients
- Collaboration aligns with Immuneering’s expanding strategy to provide a broad population of cancer patients with a wide set of treatment options -- Represents Immuneering’s fourth agreement with a pharma partner --
Ways to Trade IMRX at MEXC
How to Buy Immuneering Corporation (IMRX) Stock on MEXC
Eligible investors can buy real shares of Immuneering Corporation (IMRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Step 1: Open and Verify Your RealStocks Account
Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.
Step 2: Transfer USDT to Your RealStocks Account
Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.
Step 3: Search for IMRX and Place Your Order
Open the RealStocks trading page and search for IMRX. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.
Frequently Asked Questions (FAQ)
1.What is Immuneering Corporation (IMRX) stock price today?
Immuneering Corporation (IMRX) is currently trading at $3.74, down 2.64% ($0.10) from the previous close of $3.79. Intraday prices update in real time during regular trading hours.
2.Is IMRX stock going up or down today?
As of 2026-11-12 15:12:48, IMRX is trading at $3.74, down 2.64% ($0.10) from its previous close of $3.79. The stock has traded between $3.69 and $3.95 during today’s regular session. Past price movements do not guarantee future results.
3.What is IMRX pre-market price?
As of 2026-11-12 15:12:48, IMRX is trading at $3.91 in pre-market trading, up 3.19% ($0.12) from the previous close of $3.79. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.
4.What is IMRX after-hours price?
As of 2026-11-12 15:12:48, IMRX is trading at $3.82 in after-hours trading, up 2.14% ($0.08) from the regular-session close of $3.74. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.
5.Is IMRX stock trading now?
IMRX trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.
6.Where does IMRX sit relative to its 52-week high and low?
Over the past 52 weeks, IMRX has traded between a low of $3.35 and a high of $8.48. At $3.74, the stock is positioned 7.5% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.
7.What sector is Immuneering Corporation in?
Immuneering Corporation (IMRX) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.
8.What is Immuneering Corporation's market capitalization and where is it listed?
Immuneering Corporation is listed on the NASDAQ exchange with a market capitalization of $249.34M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.
9.How is IMRX valued in terms of P/E ratio and EPS?
IMRX trades at a P/E ratio of --, based on trailing-twelve-month EPS of $-1.03. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.
10.Does Immuneering Corporation pay a dividend?
Immuneering Corporation pays an indicated annual cash dividend of $0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.
Explore More US Stocks
Largest Market Cap
See US stocks with the highest market capitalization
Most Actively Traded
Discover today's most actively traded US stocks
Top Gainers
Browse today's leading gainers in the US stock market
Top 5 Cryptocurrencies
Explore the cryptocurrencies with the highest market capitalization
Compliance Disclosure and Data Source
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to IMRX, including Stocks, Tokenized Stocks, and Stock Futures.
Disclaimer
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Search Stocks
IMRX Stock Calculator
Estimate the value between IMRX shares and USD.
IMRX Shares to USD
IMRX Shares
IMRX
USD
USD
1.00 IMRX shares = 3.736 USD
Calculations are estimates based on the latest available price and are for reference only.